Treatment and outcomes of invasive fusariosis: review of 65 cases from the  PATH  Alliance ®  registry by Horn, David L. et al.
Original article
Treatment and outcomes of invasive fusariosis: review of 65 cases
from the PATH Alliance registry
David L. Horn,1 Alison G. Freifeld,2 Mindy G. Schuster,3 Nkechi E. Azie,4 Billy Franks4 and
Carol A. Kauffman5
1David Horn LLC, Doylestown, PA, USA, 2Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE, USA, 3Infectious Diseases
Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 4Astellas Pharma Scientific and Medical Affairs, Inc., Northbrook,
IL, USA and 5Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System and University of Michigan Medical School, Ann Arbor, MI, USA
Summary Invasive Fusarium infections occur in immunosuppressed patients, especially those
with haematological malignancies. We conducted a descriptive analysis of data from
patients with invasive fusariosis identified in the Prospective Antifungal Therapy Alli-
ance registry, which collected data on invasive fungal infections in the United States
and Canada from 2004 to 2008. In this series of 65 patients with proven (83.1%)
and probable (16.9%) invasive fusariosis, the most common underlying condition
was haematological malignancy, in which neutropenia and corticosteroid usage fre-
quently occurred. Seven patients with invasive Fusarium infections had cross-reactive
galactomannan assay results. The survival rate for all patients at 90 days was 44%,
which was an improvement compared with historical data. Disseminated disease
occurred frequently (35.4%), and patients with and without disseminated disease
had survival rates of 33% and 50%, respectively. Posaconazole and voriconazole
were the most frequently employed therapies and may be linked to the improved sur-
vival rate observed in this patient series. In summary, patients with invasive Fusari-
um infections continue to have high fatality rates, especially those with disseminated
disease. Fusarium infections should be strongly considered in the absence of Aspergil-
lus isolation in patients at high risk of mould infections with positive galactomannan
assay test results.
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Introduction
Among immunocompromised patients, Fusarium spp.
are second to Aspergillus spp. as the most common
cause of invasive mould infections.1 Fusarium infec-
tions are associated with a high mortality rate, espe-
cially in patients who have haematological
malignancies or have received an allogeneic
haematopoietic cell transplant and have severe and
persistent neutropenia or graft-versus-host disease.
The airway is the primary portal of entry for fungal
conidia, leading to lung and sinus disease in immuno-
compromised patients. Entry via the skin at sites of
trauma or breakdown may yield localised infection or
disseminated disease, depending on the degree of
immune dysfunction. The Fusarium spp. that most
frequently cause human infections include F. solani,
F. oxysporum and F. moniliforme.1–7
Therapy of infections caused by Fusarium spp. is
challenging due to a paucity of clinical trial data and
to the relative resistance of these organisms to avail-
able antifungal agents. Antifungal therapy of fusariosis
may include amphotericin B, liposomal amphotericin
B, itraconazole, voriconazole and posaconazole, either
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alone or in combination. Fusarium solani appears to be
the most resistant, but other species also are resistant
to azoles or have high amphotericin B minimum
inhibitory concentrations. Voriconazole and posaco-
nazole are more active against most Fusarium species
than other, older azole agents.1,3,5–9
Most studies of infections due to Fusarium species
are from single centres, and most of those are cancer
centres.10–13 However, Nucci et al. [9] recently
reported on 233 cases of invasive fusariosis from cen-
tres in 11 different countries. In addition, Muhammed
et al. [14] analysed 26 cases of proven and probable
fusariosis treated at Massachusetts General Hospital,
and reviewed an additional 97 cases from the medical
literature. The Prospective Antifungal Therapy (PATH)
Alliance prospectively collected data on 6845 evalu-
able patients with 7526 proven or probable invasive
fungal infections (IFIs) from 25 tertiary care centres in
the United States and Canada between 2004 and
2008.15 Using the PATH Alliance registry, we sought
to describe the epidemiology, diagnosis, treatment and
outcomes of invasive fusariosis in 65 identified
patients.
Methods
The PATH Alliance registry is a surveillance network
that has collected data prospectively from patients
with IFIs. Participating centres included those caring
for haematopoietic cell transplant recipients, solid
organ transplant recipients, haematology–oncology
patients, and general medical and surgical patients.
Data collection methods have been described in detail
previously.16 Briefly, an electronic case report form
was used to collect prospective patient data for
12 weeks after diagnosis, or until patients had died or
were lost to follow-up. Information collected included
patient demographic characteristics at baseline, under-
lying diseases and concomitant conditions, transplant
type, corticosteroid usage and/or other immunosup-
pressive therapies, absolute neutrophil count, infecting
species, site of infection and antifungal and adjunctive
therapies. Enrolment of patients was approved by the
individual institutional review boards at each of the
participating centres.
Cultures for fungi and specimens for histopathologi-
cal examination were processed and identified employ-
ing methods routinely used at each institution.
Galactomannan tests were sent at the discretion of the
PATH investigators; however, the body fluid origins of
these specimens were not known and only positive
results were recorded. Proven disseminated fusariosis
was defined as the isolation of Fusarium spp. from
blood cultures with or without multiple organ involve-
ment. Localised invasive infection was designated as
either proven or probable based on criteria published
by the European Organization for Research and Treat-
ment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group.17
The day that a Fusarium infection was diagnosed
clinically was designated as day 1. Concomitant fungal
infection was defined as an infection that occurred
within 14 days of diagnosis of a Fusarium infection.
Infections that occurred 14 days or more after a diag-
nosis of fusariosis were defined as secondary infections.
Fungal infections that may have occurred 14 days
before diagnosis of Fusarium were not evaluated. Ini-
tial therapy was designated to be that given on day 3.
Due to the large heterogeneity of the Fusarium-
infected population, descriptive statistics are reported
for baseline characteristics and subgroup analyses,
and statistical inference has been avoided. Descriptive
survival analyses are provided by the whole patient
group and by infection site. Patients who were lost to
follow-up prior to the week 12 assessment were cen-
sored on the day of their last reported activity. SAS
version 9.2/Enterprise Guide 4.2 (SAS Institute, Cary,
NC, USA) was used for statistical analyses.
Results
Baseline characteristics
Within the PATH Alliance database, 65 patients
were identified with invasive Fusarium infection
(Table 1). Fifteen patients had one or more concomi-
tant fungal infections (nine with Aspergillus spp., two
with candidemia, one with Cladosporium plus Aspergil-
lus infection and one each with Curvularia, Paecilomy-
ces and Trichosporon spp. infections), and two patients
had a secondary fungal infection [Aspergillus fumigatus
(n = 1) and Candida glabrata (n = 1)]. One patient had
both a concomitant and secondary infection (Aspergil-
lus and Curvularia spp. respectively). Of the 25 centres
in the PATH Alliance, 19 reported cases of fusariosis.
The number of patients per centre ranged from 1 to
15 [median 2.0; mean  standard deviation (SD):
3.4  3.4]. The regional distribution of cases was
South (n = 30), Midwest (n = 16), Northeast (n = 11),
West (n = 7) and Canada (n = 1).15
The mean  SD age of patients with fusariosis was
51.2  18.6 years, and the majority were male
(n = 41, 63.1%) and Caucasian (n = 51, 78.5%). The
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most common underlying condition was haematologi-
cal malignancy (n = 47, 72.3%), in which corticoste-
roid usage frequently occurred (n = 31, 66.0%).
Neutropenia (absolute neutrophil count <1000
cells mm3) at baseline was noted in 40 (61.5%)
patients. An absolute neutrophil count of
<100 cells mm3 at baseline occurred in 28 (43.1%)
patients. Among the 47 patients with a haematologi-
cal malignancy, eight (17.0%) had received an alloge-
neic haematopoietic cell transplant. A large number of
patients (n = 28, 43.1%) had a bacterial infection
within 7 days prior to diagnosis of the Fusarium
infection.
Diagnosis and sites of infection
A total of 54 (83.1%) patients had proven fusariosis
and 11 (16.9%) had probable fusariosis. Of the 65
patients with Fusarium infection, 64 (98.5%) had a
positive culture and 1 (1.5%) patient had a diagnosis
based on PCR. Twenty-seven (41.5%) patients had
supporting histopathology and one (1.5%) had a
Table 1 Underlying conditions and demographics of 65 patients with fusariosis.
Parameter All CNS Lung Sinus
Skin/soft
tissue Abdominal Endophthalmitis Disseminated1
Patients, n 65 1 10 6 21 2 2 23
Age, mean
years  SD2
51.2  18.6 39.0 56.6  18.0 50.2  21.8 51.2  21.1 65.0  12.7 66.0  2.8 47.2  16.5
Male, n (%) 41 (63.1) 1 (100) 7 (70.0) 4 (66.7) 10 (47.6) 2 (100) 2 (100) 15 (65.2)
Ethnicity, n (%)
White 51 (78.5) 0 10 (100) 3 (50.0) 17 (81.0) 2 (100) 2 (100) 17 (73.9)
Black 4 (6.2) 1 (100) 0 1 (16.7) 0 0 0 2 (8.7)
Hispanic 3 (4.6) 0 0 0 3 (14.3) 0 0 0
Asian 6 (9.2) 0 0 1 (16.7) 1 (4.8) 0 0 4 (17.4)
Other or unknown 1 (1.5) 0 0 1 (16.7) 0 0 0 0
Underlying conditions, n (%)
Haematologic
malignancy
47 (72.3) 1 (100) 3 (30.0) 6 (100) 16 (76.2) 0 0 21 (91.3)
HCT 8 (12.3) 0 1 (10.0) 0 1 (4.8) 0 0 6 (26.1)
HIV/AIDS 2 (3.1) 1 (100) 0 0 1 (4.8) 0 0 0
Diabetes mellitus 10 (15.4) 0 3 (30.0) 0 4 (19.0) 1 (50.0) 0 2 (8.7)
Solid organ
transplantation
8 (12.3) 0 6 (60.0) 0 0 0 0 2 (8.7)
Solid tumour 3 (4.6) 0 1 (10.0) 0 1 (4.8) 0 0 1 (4.3)
Surgical
(non-transplant)
9 (13.8) 0 1 (10.0) 1 (16.7) 4 (19.0) 1 (50.0) 1 (50.0) 1 (4.3)
General medicine 19 (29.2) 0 5 (50.0) 2 (33.3) 4 (19.0) 1 (50.0) 2 (100) 5 (21.7)
Concomitant infection, n (%)
Cytomegalovirus 3 (4.6) 1 (100) 0 0 0 0 0 2 (8.7)
Bacterial infection 28 (43.1) 0 3 (30.0) 2 (33.3) 8 (38.1) 1 (50.0) 1 (50.0) 13 (56.5)
Fungal infection 18 (27.7) 0 4 (40.0) 4 (66.7) 3 (14.3) 0 1 (50.0) 6 (26.1)
Corticosteroid
therapy, n (%)
31 (47.7) 1 (100) 3 (30.0) 2 (33.3) 8 (38.1) 0 0 17 (81.0)
Neutropenia (baseline)
ANC <100,
mean  SD days
15.7  12.8 0 0 8.8  14.4 13.5  12.4 0 0 21.8  10.7
ANC <500,
mean  SD days
18.6  11.9 0 8.5  12.0 18.8  11.2 16.1  13.2 0 0 22.6  10.2
ANC <1000,
mean  SD days
20.8  10.7 0 14.5  19.1 20.8  10.9 18.8  11.5 0 0 23.9  9.1
ANC, absolute neutrophil count; CNS, central nervous system; SD, standard deviation; HCT, haematopoietic cell transplant.
1There were 23 patients with disseminated disease: 10 with fungaemia only, four patients with blood and skin/soft tissue; two patients
with blood, lung and skin/soft tissue; one patient with blood, lung, sinus and skin/soft tissue; one patient with blood, lung and sinus;
one patient with blood and lung; one patient with blood and catheter site; one patient with blood and central nervous system; one
patient with sinus, skin/soft tissue, other and eye; one patient with sinus and skin/soft tissue.
2Range was 4–79 years with two paediatric patients aged 4 and 7 years.
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supporting molecular diagnosis. Twenty-two (33.8%)
patients had blood cultures that yielded Fusarium spp.
There were 23 (35.4%) patients with disseminated
disease: 10 with fungaemia only, four patients with
blood and skin/soft tissue; two patients with blood,
lung and skin/soft tissue; one patient with blood, lung,
sinus and skin/soft tissue; one patient with blood, lung
and sinus; one patient with blood and lung; one
patient with blood and catheter site; one patient with
blood and central nervous system; one patient
with sinus, skin/soft tissue, other and eye; one patient
with sinus and skin/soft tissue. In non-disseminated
disease (n = 42; 64.6%), the distribution of infection
sites was skin/soft tissue (n = 21; 32.3%), lung
(n = 10, 15.4%), sinus (n = 6, 9.2%), eye (n = 2,
3.1%), abdomen (n = 2, 3.1%) and central nervous
system (n = 1, 1.5%).
Ten patients, all of whom had a haematological
malignancy, had positive galactomannan assays
(Table 2). Aspergillus was not isolated in culture in
seven of these 10 patients, and of the seven, one
patient each had concurrent isolation of Candida par-
apsilosis or Trichosporon spp. in addition to Fusarium.
Treatment and outcomes
Forty-six (70.8%) patients received antifungal therapy
(including agents not recommended for therapy of
Fusarium infections) on day 3, the day designated by
the study at which initial therapy was evaluated
(Table 3). Twenty-four patients received monotherapy
and 22 patients received combination therapy. For
monotherapy, voriconazole was most commonly
administered, and an amphotericin B formulation was
the second most commonly administered agent. For
combination therapy, voriconazole plus amphotericin
B formulations were most commonly used. The second
most commonly used combination therapy was vorico-
nazole plus an amphotericin B formulation plus an
echinocandin. Nineteen patients did not have treat-
ment recorded on day 3, including four patients with
missing data, four who had not received antifungal
therapy by day 3 and 11 who had received therapy





in culture Site of Fusarium Infection Comment
A No Yes Blood; skin/soft tissue A. terreus isolated from BAL culture
B No Yes Lung A. flavus and A. terreus isolated from BAL culture2
C Yes No Sinus Aspergillus not identified but presumed in lung2
D Yes No Skin/soft tissue Aspergillus not identified but presumed in lung2
E No Yes Blood A. flavus isolated from BAL culture
F Yes No Lung Fusarium only infection
G No No Blood; lung; skin/soft tissue Candida parapsilosis isolated from blood
H No No Blood; lung; skin/soft tissue Trichosporon also isolated
I Yes No Blood; skin/soft tissue Fusarium only infection
J Yes No Skin/soft tissue Fusarium only infection
BAL, bronchoalveolar lavage.
1All patients had haematological malignancy and were neutropenic except patient B who had haematological malignancy only; patients
A, B, F, G, H, I also had prior corticosteroid treatment; patient E also had prior corticosteroid treatment, solid tumour and surgery.
2These patients were diagnosed with a concomitant infection (invasive fusariosis + invasive aspergillosis).
Table 3 Antifungal therapies administered on days 3, 10 and
30.1
Parameter
Patients (N = 65)
Day 3 Day 10 Day 30
Monotherapy
Echinocandin 3 1 0
Amphotericin B2 5 2 0
Fluconazole 1 0 0
Voriconazole 12 12 15
Posaconazole 2 3 5
Blinded 1 1 0
Combination therapy
Voriconazole + echinocandin 4 3 1
Voriconazole + amphotericin B 10 10 7
Amphotericin B + echinocandin 1 3 0
Voriconazole + amphotericin B +
echinocandin
53 14 0
Posaconazole + amphotericin B 2 3 0
1Complete treatment records were not available for 19 patients.
2All patients received a lipid formulation of amphotericin B
except where noted.
3Two of these patients received amphotericin B deoxycholate.
4This patient received amphotericin B deoxycholate.
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before day 3 but no actual therapy on day 3 itself. Six
patients died before day 3.
The pattern of antifungal agents administered on
day 10 was largely similar to day 3, except for less
usage of amphotericin B formulations as monotherapy
and a reduction in overall usage of echinocandins
(Table 3). On day 30, 20 patients were receiving
monotherapy with voriconazole or posaconazole, and
eight patients were receiving combination therapy
with voriconazole plus an amphotericin B formulation
or voriconazole plus an echinocandin. Surgery was
performed in nine patients (13.8%). Procedures
included debridement (n = 7), resection/excision
(n = 2) and drainage (n = 1).
The 12-week Kaplan–Meier survival rate for all
patients was 44% (Fig. 1), and deaths occurred
throughout the follow-up period. Patients with and
without disseminated disease had survival rates of
33% and 50% respectively (Fig. 1). The survival rates
of patients with non-disseminated disease of the skin/
soft tissue, lung and sinuses were 45%, 68% and 50%
respectively.
Discussion
This large multicentre experience of proven and proba-
ble fusariosis expands our knowledge of this often dev-
astating infection. We report on the epidemiology,
therapy and outcomes of 65 patients with invasive
Fusarium infections in 19 of the 25 North American
medical centres participating in the PATH Alliance
registry from 2004 to 2008. Most patients had a hae-
matological malignancy (72.3%), and 17% of these
patients had received a haematopoietic cell transplant.
Neutropenia and corticosteroids were commonly found
as risk factors. The majority of patients (83.1%) had
proven fusariosis. Fungaemia and disseminated disease
occurred frequently in our series, as has been noted in
other reports.6
Ten patients had a positive galactomannan assay, of
whom only three had culture evidence of Aspergillus
spp. False-positive or cross-reactive galactomannan
assays have been reported previously with Fusarium
infections. Tortorano and colleagues have noted 10 of
12 patients with haematological malignancy and dis-
seminated/deep-seated Fusarium infections as having
positive galactomannan assays in the absence of
Aspergillus isolation in culture.18 In a more recent
report, Nucci et al. [19] identified 15 of 18 patients
with invasive fusariosis with a positive galactomannan
assay. Eleven of the 15 patients had a positive galacto-
mannan assay prior to diagnosis of invasive fusariosis.
It appears that cross-reactive results for galactoman-
nan assays may be recorded frequently in patients
with Fusarium infections. Fusarium infections should
be considered in the absence of Aspergillus isolation in
patients at high risk of mould infections with positive
galactomannan assay test results.
A similar proportion of patients received monothera-
py vs. combination therapy as initial therapy. For
monotherapy, voriconazole or an amphotericin B for-
mulation was most commonly used. For combination
therapy, voriconazole with an amphotericin B formu-
lation was most commonly administered. By day 30,
proportionally fewer patients were receiving combina-
tion therapy. On day 30, 20 patients were receiving
monotherapy with voriconazole or posaconazole, and
eight patients were receiving combination therapy. A
similar reliance on voriconazole and combination ther-
apy was also recently reported in a large multicentre
experience in 11 countries from 2001 to 2011.9
(a)
(b)
Figure 1 Survival rates for 65 patients who had invasive fusario-
sis. Overall survival (a) and Disseminated vs. Non-disseminated
disease (b).
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In this study, survival at 90 days was 44%. This
survival rate was strikingly similar to that recently
reported by Nucci et al. [9], and appears to be an
improvement compared with a 2003 report of 84
patients who had similar risk factors, including hae-
matological malignancies, neutropenia and corticoste-
roid usage. In that study, survival at 90 days was
only 21%.20 This improvement in survival may be due
to the availability of triazole antifungal agents, includ-
ing voriconazole and posaconazole. In this study, the
majority of patients received voriconazole, either as
monotherapy or in combination with other agents. In
a 2010 report, 73 patients with invasive fusariosis
(60% with haematological malignancies) were treated
with voriconazole and survival was 42% at 90 days.
Combination therapy in 13 patients was reported to
be no better than voriconazole monotherapy.11 In the
present series, patients with disseminated disease had
a lower survival rate (33%) than those who had local-
ised disease (50%). The survival rate appeared best in
patients with disease isolated to the lung (68%).
Limitations of our study include an inability to cal-
culate the incidence of invasive fusariosis due to a lack
of information on the total number of at-risk patients,
differences in clinical practices across different medical
institutions, limited data regarding galactomannan
assays, limitations in follow-up and an inability to dis-
tinguish between sequential and concomitant therapy.
Other limitations that prevented robust statistical infer-
ence of treatment outcomes included the large hetero-
geneity of the patients reported and the likely presence
of bias in the selection of antifungal therapy based on
a mix of concomitant fungal and bacterial infections
and comorbid conditions. In addition, data regarding
identification of Fusarium isolates at the species level
were not collected.
Conclusions
In this series of 65 patients with invasive Fusarium
infections, the most common underlying condition was
haematological malignancy, in which neutropenia and
corticosteroid usage frequently occurred. Results from
this analysis also showed that cross-reactive galacto-
mannan assays may occur frequently in patients with
Fusarium infections. Therefore, Fusarium infections
should be strongly considered in the absence of Asper-
gillus isolation in patients who are at high risk of mould
infections and who have positive galactomannan assay
test results. Patients with fusariosis continue to have
very high fatality rates, especially those with dissemi-
nated disease. However, survival appears improved
compared with historical data. The frequent use of po-
saconazole and voriconazole may be linked to the
improved rates of survival observed in this patient ser-
ies. Clinical studies that can clarify effective treatment
strategies for this often fatal infection are warranted.
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